Burning Rock Biotech (NASDAQ:BNR) Trading 0.1% Higher – Still a Buy?

Burning Rock Biotech Limited (NASDAQ:BNR)’s stock price was up 0.1% during mid-day trading on Tuesday . The stock traded as high as $7.39 and last traded at $7.06. Approximately 8,916 shares were traded during trading, an increase of 79% from the average daily volume of 4,979 shares. The stock had previously closed at $7.05.

Burning Rock Biotech Price Performance

The business’s fifty day moving average price is $5.55 and its 200-day moving average price is $5.27. The stock has a market capitalization of $72.32 million, a PE ratio of -2.35 and a beta of 0.55.

Institutional Trading of Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. SkyView Investment Advisors LLC bought a new stake in Burning Rock Biotech Limited (NASDAQ:BNR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned about 0.10% of Burning Rock Biotech as of its most recent SEC filing. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.